Henry Schein, Inc. is a global distributor of medical and dental supplies, pharmaceuticals, vaccines, and equipment. The company provides business, clinical, technology, and supply chain solutions to office-based dental and medical practitioners, dental laboratories, government and institutional healthcare clinics, and alternate care sites. Its operations include a centralized and automated distribution network offering over 300,000 branded and corporate brand products. Henry Schein also offers practice management software, revenue cycle management, and patient relationship management solutions through its Henry Schein One platform. The company serves customers in multiple countries and territories, with operations or affiliates worldwide. Founded in 1932, Henry Schein has grown through acquisitions and organic expansion, maintaining a network of distribution and manufacturing centers. The company supports healthcare professionals with integrated sales and marketing approaches, including targeted direct marketing and digital platforms.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Distribution Homepage henryschein.com
Sector Healthcare IR page investor.henryschein.com/overview/default.aspx
Tags
dental supplies, medical supplies, pharmaceuticals, vaccines, practice management software, revenue cycle management, patient relationship management, healthcare distribution, clinical solutions, supply chain solutions, Henry Schein One, Henry Schein International, Henry Schein Orthodontics, Henry Schein Special Markets
Press page —

Metrics

Valuation  
Market cap $ 9.282B
Market cap (USD) $ 9.282B
P/E 23.01
PEG —
P/BV 2.94
P/S 0.68
P/OCF 13.51
P/FCF 16.60
Dividend yield —
Turnover / mcap —
Returns  
ROE 12.0%
ROI 6.3%
ROIC 7.9%
Profit margin 3.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -9.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 95.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 52
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 13.184B 12.673B 12.339B 12.647B 12.401B 10.119B 9.986B 13.202B 12.462B 11.572B 10.63B 10.371B 9.561B 8.94B 8.53B 7.527B 6.538B 6.395B 5.92B 5.153B 4.636B 4.06B 3.354B 2.825B 2.558B 2.382B
Net profit 398M 390M 416M 538M 631.232M 403.794M 694.734M 535.881M 406.299M 506.778M 479.058M 466.077M 431.554M 388.076M 367.661M 325.789M 311.153M 243.143M 215.173M 163.759M 151.326M 128.183M 137.51M 117.987M 87.373M 56.749M
Free cash flow 573M 700M 353M 506M 630.565M 550.081M 577.868M 594.069M 464.014M 545.282M 515.157M 510.388M 603.96M 356.862M 509.449M 349.874M 345.263M 333.779M 213.39M 168.317M 214.312M 153.162M 89.865M 87.126M 144.784M 123.251M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 75.58 69.2 75.71 79.87 77.53 66.86 66.72 78.52 69.88 151.71 158.19 136.15 114.26 80.43 64.42 61.39 52.6 36.69 61.4 49.56 — — — — — —
Price performance 12m 0.09 -0.09 -0.05 0.03 0.16 0 -0.15 0.12 -0.54 -0.04 0.16 0.19 0.42 0.25 0.05 0.17 0.43 -0.4 0.24 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.25B 1.47B 1.6B 1.25B 1.42B 1.45B 1.44B 1.86B 1.48B 1.65B
↳ YoY growth +2.0% +17.2% +9.1% -22.3% +14.3% +1.9% -0.7% +29.2% -20.5% +11.4%
↳ 5y CAGR +7.1% +7.7% +8.7% +2.0% +3.0% +3.0% -0.4% +3.0% +3.5% +3.0%
Borrowings, current (USD) 65.9M 16.7M 8.96M 24M 73.4M 50.5M 103M 264M 650M 764M
Borrowings, non-current (USD) 715M 908M 1B 623M 516M 811M 1.04B 1.94B 1.83B 2.31B
Lease liabilities (USD) — — 0.00 247M 309M 351M 358M 398M 340M 336M
Cash and deposits (USD) 62.4M 175M 80.2M 106M 421M 118M 117M 171M 122M 156M
Intangible assets (USD) 621M 670M 584M 573M 479M 668M 587M 916M 1.02B 1.02B
Right-of-use assets (USD) — — 0.00 232M 289M 325M 284M 325M 293M 301M
Net debt (borrowings + leases - cash) (USD) 719M 750M 933M 788M 477M 1.09B 1.37B 2.43B 2.7B 3.25B
Cash flow detail
Operating cash flow (USD) 615M 546M 685M 654M 599M 710M 602M 500M 848M 712M
Purchases of property, plant and equipment (USD) -70.2M -81.5M -90.6M -76.2M -48.8M -79M -96M -147M -148M -139M
Change in receivables (cash effect) (USD) -1.9M -160M -147M -72.7M -189M 4.16M -7M -327M 315M -124M
Change in inventories (cash effect) (USD) -105M -175M -84.8M 14.7M -31.8M -295M -126M 231M -59M -95M
Change in payables (cash effect) (USD) -25.6M 88.9M 242M 161M 224M 84.7M -96M -56M -163M 216M
Share buybacks (cash effect) (USD) -550M -450M -200M -525M -73.8M -401M -485M -250M -385M -850M
Interest paid (cash effect) (USD) -29.4M -49.3M -72.3M -54.7M -43.1M -29.5M -47M -84M -132M -151M
Income taxes paid (cash effect) (USD) -205M -222M -248M -177M -207M -242M -265M -218M -144M -128M
Share-based compensation (USD) 58.2M 42.3M 36.2M 44.9M 8.79M 78.4M 54M 39M 39M 39M
Operating cash flow before change in receivables (USD) 617M 705M 832M 727M 788M 705M 609M 827M 533M 836M
Free cash flow (OCF - PPE - intangibles) (USD) 545M 464M 594M 578M 550M 631M 506M 353M 700M 573M
Income detail
Total comprehensive income (USD) 457M 654M 429M 705M 475M 591M 497M 468M 201M 604M
Comprehensive income to owners (USD) 410M 593M 417M 683M 463M 568M 476M 443M 217M 551M
Provision for credit losses (USD) 2.65M 9.37M 15.1M 12.6M 35.1M -7.75M 5M 18M 14M 16M
Credit cost ratio (credit losses / average receivables) (%) 0.2% 0.7% 1.0% 0.9% 2.6% 0.5% 0.3% 1.1% 0.8% 1.0%
Reported Feb 21, 2017 Feb 21, 2018 May 7, 2019 Feb 20, 2020 Feb 17, 2021 May 3, 2022 May 9, 2023 Feb 28, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

• Company will exclude acquisition-related remeasurement gains from non-GAAP financial results.

This change better reflects

underlying operating performance and improves comparability across reporting periods

• FY2026 non-GAAP diluted EPS guidance updated to $5.42 to $5.48 solely to reflect the change

MELVILLE, N.Y.,

November 16, 2026 –

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-

based dental and medical practitioners, today announced an update to its presentation of certain non-GAAP financial measures.

Beginning with its fourth-quarter 2026 financial results, Henry Schein will exclude the gains resulting from the remeasurement to fair value of

previously held equity interests from its non-GAAP financial results. These gains arise when the Company acquires a controlling interest in an entity in

which it previously held a non-controlling equity interest. Management believes excluding these gains better reflects underlying operating performance

and improves comparability across reporting periods.

This voluntary change does not affect the Company’s reported GAAP financial results.

11/05/2026

Download this Press Release(opens in new window)PDF 99 KB

MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in November and December:

  • Jefferies Healthcare Conference at the Waldorf Hilton, London on November 17, 2026, at 9:00 a.m. Greenwich Time/4:00 a.m. Eastern time.
  • Piper Sandler’s Healthcare Conference at the Lotte New York Palace Hotel, New York on December 1, 2026, at 9:00 a.m. Eastern time.

Henry Schein’s presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts . Replays will be available on the Henry Schein website following the presentations.

**About Henry Schein, Inc.
**Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare customers. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.

11/03/2026

Download this Press Release(opens in new window)PDF 220 KB

  • Q3 2026 GAAP diluted EPS of $1.06, up 26.2% versus prior year; Q3 2026 non-GAAP diluted EPS of $1.56, up 13.0% versus prior year
  • 4.0% total sales growth, driven by 8.6% U.S. dental merchandise sales growth due primarily to volume from market share gains
  • Raises FY2026 guidance for non-GAAP diluted EPS(A) to $5.50 to $5.56 and Adjusted EBITDA growth to high-single-digits reflecting strong operating performance, net tariff refund benefits, and targeted, limited growth-investments 

MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 26, 2026. The Company reported $3.5 billion in sales with total growth of 4.0%, and 3.1% internally in local currencies. GAAP earnings per share grew 26.2% versus the prior year. Non-GAAP earnings per share grew 13.0%, or 19.1% when excluding current-quarter net tariff refunds and the prior-year remeasurement gains (refer to Exhibit D).

“We delivered another strong quarter that increases our confidence in the momentum we are building at Henry Schein. I am very pleased with the U.S. dental merchandise sales growth of 8.6% driven primarily by volume in a stable market and our 19% adjusted earnings per share growth4,” said Fred Lowery, Chief Executive Officer of Henry Schein. “Our strategy is translating into stronger financial results. We are gaining share in key businesses, improving our portfolio mix, maintaining a disciplined approach to capital allocation, and realizing the benefits of our value creation initiatives,” Mr. Lowery added.

Third Quarter 2026 Financial Results

  • Total net sales for the quarter were $3.5 billion, an increase of 4.0% in total compared to the third quarter of 2025, reflecting 3.1% internal sales growth, 0.7% sales growth from acquisitions, and a 0.2% increase resulting from foreign currency exchange. Third quarter sales growth is detailed in Exhibit A 1.

  • Global Distribution and Value-Added Services sales for the quarter increased 3.7% in total, reflecting 2.9% internal sales growth, 0.5% sales growth from acquisitions, and a 0.3% increase from foreign currency exchange compared with the third quarter of 2025. The main components compared with the third quarter of 2025 are:

    • Global Dental Distribution merchandise sales for the quarter increased 7.0% in total, and by 5.1% internal sales growth, compared with the third quarter of 2025.
    • Global Dental Distribution equipment sales for the quarter increased 2.3% in total, and by 2.4% internal sales growth, compared with the third quarter of 2025.
    • Global Medical Distribution sales for the quarter increased 1.1% in total, and by 1.0% internal sales growth, compared with the third quarter of 2025.
    • Global Value-Added Services sales for the quarter decreased 4.8%, on both a reported and internal sales growth basis, compared with the third quarter of 2025.
  • Global Specialty Products sales for the quarter increased 6.1% in total, reflecting 3.4% internal sales growth, 2.6% sales growth from acquisitions, and a 0.1% increase resulting from foreign currency exchange, compared with the third quarter of 2025.

  • Global Technology sales for the quarter increased 5.2% in total, reflecting 6.5% internal sales growth, 1.3% sales decrease due to a business disposal, and no impact from foreign currency exchange, compared with the third quarter of 2025.

  • GAAP net income2 for the quarter was $119 million. GAAP diluted earnings per share were $1.06 per diluted share 3, up 26.2% compared with the third quarter of 2025.

  • Non-GAAP net income2 for the quarter was $175 million. Non-GAAP diluted earnings per share were $1.56 per diluted share, up 13.0% compared with the third quarter of 2025.

    • The Company recognized a $0.19 per diluted share 3,4 net benefit from tariff refunds in the third quarter of 2026, and a $0.23 per diluted share 3,4 remeasurement gain in the third quarter of 2025, included in our GAAP and non-GAAP results.
    • Excluding these items, non-GAAP diluted EPS was $1.37 4 compared with $1.15 4 in the prior-year period, an increase of 19.1%.
  • Adjusted EBITDA5 for the quarter was $321 million, compared with Adjusted EBITDA for the third quarter 2025 of $295 million, with Adjusted EBITDA margin growing 40 basis points to 9.24%.

Year-to-Date Financial Results

  • Total net sales for the first nine months of 2026 were $10.3 billion, an increase of 5.6% in total compared to the first nine months of 2025, reflecting 3.4% internal sales growth, 0.7% sales growth from acquisitions, and a 1.5% increase resulting from foreign currency exchange. Year-to-date sales growth is detailed in Exhibit A 1.
  • GAAP net income2 for the first nine months of 2026 was $320 million. GAAP diluted earnings per share were $2.80 per diluted share 3, up 15.7% compared with the first nine months of 2025.
  • Non-GAAP net income2 for the first nine months of 2026 was $473 million. Non-GAAP diluted earnings per share were $4.14 per diluted share 3, up 14.0% compared with the first nine months of 2025.
  • Adjusted EBITDA5 for the first nine months of 2026 was $898 million, compared with Adjusted EBITDA for the first nine months of 2025 of $810 million, with Adjusted EBITDA margin growing 41 basis points to 8.72%.

Share Repurchases

During the third quarter of 2026, the Company repurchased approximately 1.4 million shares of common stock at an average price of $86.67 per share for a total of $125 million.

For the year-to-date, the Company repurchased approximately 5.7 million shares of common stock at an average price of $79.50 per share for a total of $450 million.

At the end of the quarter, Henry Schein had approximately $330 million authorized and available for future stock repurchases.

2026 Financial Guidance

Henry Schein today raised its financial guidance for 2026. Guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs, amortization expense of acquired intangible assets, the impairment of intangible assets, changes in contingent consideration, select implementation-related costs supporting value creation initiatives, and litigation settlements. This guidance also assumes that foreign currency exchange rates remain generally consistent with current levels.

The Company’s FY2026 non-GAAP diluted EPS guidance includes the net benefit from tariff refunds recognized in the third quarter, targeted and limited growth-investments in the fourth quarter which will contribute to growth in 2027, and improved underlying business performance. The updated guidance assumes no significant tariff refunds or remeasurement gains for the remainder of 2026. The changes to the Company’s financial guidance are summarized below:

Updated Prior
Guidance Guidance
2026 non-GAAP diluted EPS3 $5.50 to $5.56 $5.29 to $5.39
2026 total sales growth 4.5% to 5.5% 4.5% to 5.5%
2026 Adjusted EBITDA growth High-single-digits Mid to high-single-digits

(A) Adjustments to 2026 GAAP Net Income and Diluted EPS

The Company is providing guidance for 2026 diluted EPS and for 2026 Adjusted EBITDA on a non-GAAP basis, as noted above. The Company is not providing a reconciliation of its 2026 non-GAAP diluted EPS guidance to its projected 2026 diluted EPS prepared on a GAAP basis, or its 2026 Adjusted EBITDA guidance to net income prepared on a GAAP basis. This is because the Company is unable to provide without unreasonable effort an estimate of restructuring expenses and related or similar costs, including its ongoing value creation initiatives, and the corresponding tax effect, which will be included in the Company’s 2026 diluted EPS and net income, prepared on a GAAP basis. The inability to provide this reconciliation is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and timing of related costs.

Management does not believe these items are representative of the Company’s underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Third-Quarter 2026 Conference Call Webcast

The Company will hold a conference call to discuss third-quarter 2026 financial results today, beginning at 8:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein’s website by visiting https://investor.henryschein.com/webcasts . In addition, a replay will be available beginning shortly after the call has ended for a period of one week.

The Company will be posting slides that provide a summary of its third-quarter 2026 financial results on its website at https://investor.henryschein.com/financials/quarterly-results/

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare customers. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.

Prompts

Henry Schein, Inc. (ticker HSIC), listed in United States.

Company History

Date Change Detail
Jul 20, 2006 Renamed SCHEIN HENRY INC → HENRY SCHEIN INC

ETFs Holding Henry Schein, Inc.

ETF Weight in ETF Shares Market value As of
CWS 4.48% 59,903 $ 4.968M Nov 17, 2026
FLV 1.72% 73,116 $ 6.566M Aug 31, 2026
TAX 1.13% 3,205 $ 287.809K Aug 31, 2026
PINK 0.90% 36,319 $ 3.012M Nov 17, 2026
BSMC 0.79% 15,711 $ 1.312M Jun 30, 2026
HUSV 0.38% 2,551 $ 216.733K Nov 16, 2026
FBCV 0.36% 7,509 $ 643.897K Jul 31, 2026
GOP 0.30% 3,088 $ 262.356K Nov 17, 2026
DFAT 0.26% 963,703 $ 83.013M Nov 12, 2026
AFMC 0.24% 7,488 $ 636.18K Nov 16, 2026
VFMF 0.21% 22,777 $ 2.045M Aug 31, 2026
DFAS 0.21% 806,764 $ 69.495M Nov 12, 2026
AVIE 0.18% 350 $ 29.736K Nov 16, 2026
VFVA 0.11% 11,594 $ 1.041M Aug 31, 2026
IEDI 0.10% 316 $ 27.097K Jul 31, 2026
FTLS 0.09% 26,888 $ 0.00 Nov 16, 2026
JSTC 0.08% 2,688 $ 228.372K Nov 17, 2026
MSSM 0.06% 4,775 $ 428.795K Aug 31, 2026
VFQY 0.06% 3,240 $ 290.952K Aug 31, 2026
DXUV 0.06% 40,713 $ 3.507M Nov 12, 2026
DFUV 0.06% 101,137 $ 8.712M Nov 12, 2026
DFSU 0.05% 13,440 $ 1.158M Nov 12, 2026
DFAC 0.05% 473,291 $ 40.769M Nov 12, 2026
IALT 0.04% 40,979 $ 3.482M Nov 16, 2026
CAPE 0.04% 1,090 $ 91.037K Jun 30, 2026
GVLU 0.03% 889 $ 75.529K Nov 17, 2026
AAUS 0.03% 2,109 $ 170K Nov 18, 2026
DCOR 0.03% 141,526 $ 12.191M Nov 12, 2026
DFAU 0.02% 27,053 $ 2.33M Nov 12, 2026
EBI 0.01% 1,088 $ 97.702K Aug 31, 2026
DFUS 0.01% 28,725 $ 2.474M Nov 12, 2026
HCMT 0.01% 674 $ 57.796K Jul 31, 2026
CSHP 0.01% 226 $ 19.201K Nov 16, 2026
MSLC 0.01% 4,474 $ 401.765K Aug 31, 2026
DFSV 0.00% 99 $ 8,527.86 Nov 12, 2026
AVLC 0.00% 4 $ 339.84 Nov 16, 2026
CORO 0.00% 60 $ 5,129.08 Nov 16, 2026
GSPY 0.00% 394 $ 33.474K Nov 17, 2026